Testimony, Comments, & Letters

;

Support for Rhode Island bill banning copay accumlators

Apr 30, 2025

When patients are forced to forego their medications due to high costs, the consequences are severe—not just for individual health outcomes, but also for public health and healthcare system costs. Policies that limit access to copay assistance exacerbate these challenges, disproportionately affecting those who are already vulnerable. House Bill 6209 represents an essential safeguard against harmful insurer practices, ensuring equitable access to life-saving treatments for Rhode Island residents.

read more

Comments to Oregon PDAB on HIV medication affordability reviews

Apr 14, 2025

We strongly believe that affordability reviews of HIV medications are unnecessary, given the comprehensive safety net programs that effectively ensure access to lifesaving treatments. Any future pricing interventions, such as the imposition of UPLs, could destabilize this well-established network, threatening access to care for people living with HIV. Programs like the Ryan White HIV/AIDS Program, the 340B program, and manufacturer copay assistance are critical to sustaining the progress and innovation that have transformed HIV treatment.

read more

House testimony on FY26 appropriations for HIV and hepatitis programs

Apr 9, 2025

This testimony is in support of funding for the following initiatives, programs and divisions at the Department of Health and Human Services: Ending the HIV Epidemic Initiative—$395 million for the CDC Division of HIV/AIDS Prevention, $358.6 million for the HRSA Ryan White HIV/AIDS Program, $207.3 million for the HRSA Community Health Centers, and $52 million for the Indian Health Service; Ryan White HIV/AIDS Program—$3.024 billion; CDC Division of HIV Prevention—$822.7 million; CDC Division of Viral Hepatitis—$150 million; and the HHS Office of Infectious Disease and HIV/AIDS Policy—$20 million. The HIV+Hepatitis Policy Institute also supports maintaining and funding CDC’s Eliminating Opioid-Related Infectious Diseases Program and Division of School and Adolescent Health; the Minority HIV/AIDS Initiative; AIDS Research 2 at the NIH; the Title X Family Planning Program; the Teen Pregnancy Prevention Program; and the SAMHSA HIV Block Grant.

read more

Testimony in support of New Jersey A5217 to ban copay accumulators

Mar 17, 2025

The HIV+Hepatitis Policy Institute, a leading organization advocating for equitable and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic health conditions, strongly supports Assembly Bill 5217. This vital legislation ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums.

read more

Testimony in support of North Dakota HB1216 to ensure all copays count toward patients’ deductible and out-of-pocket costs

Mar 17, 2025

The HIV+Hepatitis Policy Institute, a leading organization advocating for equitable and affordable healthcare for individuals living with or at risk of HIV, hepatitis, and other chronic health conditions, strongly supports House Bill 1216. This vital legislation ensures that health insurers accept and count payments made on behalf of patients toward their deductibles and out-of-pocket maximums.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest